Disease relevance of Hpmcas

• CONCLUSIONS: The conclusion of the earlier study indicating that treatment with HPMCAS at doses up to and including 2500 mg/kg did not produce developmental toxicity was confirmed with these studies [1].

High impact information on Hpmcas

• For HPMC and HPMCAS, thermal analysis indicated that the glass transition temperature (T(g)) of the solid dispersions were not significantly different from that of felodipine alone, whereas an increase in T(g) was observed for the PVP containing solid dispersions [2].
• To develop a new colon targeting formulation, which can suppress drug release completely during 12 h in the stomach and release the drug rapidly after a lag time of 3+/-1 h in the small intestine, the use of press-coated tablets with hydroxypropylmethylcellulose acetate succinate (HPMCAS) in the outer shell was investigated [3].
• The major aim of the present work was to study the effects of various formulation and processing parameters on the resulting drug release kinetics from theophylline matrix pellets coated with aqueous hydroxypropyl methylcellulose acetate succinate (HPMCAS) dispersions [4].
• A newly commercialized high-resolution ultrasonic spectrometer was evaluated for simultaneously measuring concentrations of a model excipient (hypromellose acetate succinate polymer, HPMCAS, CAS No. 71138-97-1) and a model drug (Fenofibrate, CAS No. 49562-28-9) in acetone solution [5].
• 8. It was found that the amount of HPMCAS in the tablet correlates with gastric juice resistance [6].

Biological context of Hpmcas

• Open storage at elevated temperatures and humidities caused changes in the surface structure of HPMCAS coatings, consisting of a smoothing of the originally somewhat porous film and sticking [7].
• The active ingredient pancreatin induced hydrolysis of the ester based film-former hydroxypropyl methylcellulose acetate succinate (HPMCAS) [7].
• Female rats received HPMCAS for 22 days, from 14 days prior to mating up to Day 7 of gestation [8].
• Embryo/fetal development studies with hydroxypropyl methylcellulose acetate succinate (HPMCAS) in rats and rabbits [1].
• The administration of HPMCAS during a period of organogenesis produced no embryotoxic and teratogenic effects as well as no influence on behavior, appearance and growth of animals [9].

Anatomical context of Hpmcas

• No external, internal and skeletal anomalies attributable to HPMCAS were observed in the fetuses [8].
• HPMCAS appeared to have no significant effect on the central nervous system, autonomic nervous system and cardiovascular system [10].

Associations of Hpmcas with other chemical compounds

• Effect of magnesium stearate (MgSt) or calcium stearate (CaSt) on the dissolution profiles of diltiazem hydrochloride in the core of press-coated (PC) tablets with an outer shell composed of hydroxypropylmethylcellulose acetate succinate (HPMCAS) was evaluated by porosity and changes in IR spectra of tablets [11].
• Pancreatin pellets, placebo pellets and tablets containing vitamin B2 were coated with various aqueous and organic enteric polymers, HPMCAS, HP, Eudragit L 100-55, Eudragit L 30 D-55, CAP, CAT, CMEC and PVAP, comparatively investigated and tested for storage stability [7].

Analytical, diagnostic and therapeutic context of Hpmcas

• 4)Various biochemical and physiological abnormalities in rats were noted in all groups (including the control groups) in the toxicity studies, but there appeared to be no significant dose-related finding attributable to the administration of HPMCAS [12].

References